What was recalled
In March of 2020, a significant recall was issued involving specific prescription medications manufactured by Novartis. The products at the center of this safety alert are blister packages of Sandimmune and Neoral, both of which contain cyclosporine capsules (USP). Specifically, the recall targets the 100 mg soft gelatin capsule versions of these drugs. It is important to understand that this action was not taken because the medication itself was defective or ineffective; rather, it was a precautionary measure addressing the packaging used to distribute these critical prescriptions.
Sandimmune is an immunosuppressant medication used to prevent organ rejection in patients who have received kidney, liver, or heart transplants. Neoral is a modified formulation of cyclosporine, often prescribed for similar conditions including severe rheumatoid arthritis and certain types of dermatitis. While the chemical composition of the drugs remains unchanged and safe for use, the physical containers holding them failed to meet federal safety standards. The affected items are identified by their specific National Drug Code (NDC) numbers, lot numbers, and expiration dates. For Sandimmune 100 mg capsules, the recalled NDCs are 0078-0241-15 and 0078-0241-61. The corresponding lot numbers for this product include APCA136 (expiring 09/2020), APCA339 (expiring 02/2021), APCA793 (expiring 01/2022), and APCC238 (expiring 07/2022).
For Neoral MODIFIED 100 mg capsules, the affected NDCs are 0078-0248-15 and 0078-0248-61. The specific lot numbers for Neoral included in this recall are APCA437 (expiring 07/2020) and APCA979 (expiring 03/2021). These packages typically contain multiple blister cards; Sandimmune packages include three blister cards with ten capsules each, while Neoral packages contain five blister cards with six capsules each. The outer packaging clearly displays the Novartis logo, the medication name, dosage, NDC, lot number, and expiration date, allowing patients to verify if their specific supply is part of this batch.
This recall was officially announced by the U.S. Consumer Product Safety Commission (CPSC) on March 18, 2020. The scope of the recall covers these specific blister packages distributed across the United States. If you have been prescribed either Sandimmune or Neoral at the 100 mg strength, it is vital to check your medication bottles and blister cards against the lot numbers listed above. While no incidents of poisoning or adverse events were reported during this period, the potential risk warranted an immediate and widespread recall to ensure patient safety and compliance with the Poison Prevention Packaging Act.
The hazard, explained
To understand why this recall matters, we need to look at the specific physical failure involved. The U.S. Consumer Product Safety Commission (CPSC) is overseeing this action because the blister packages for these Novartis medications do not meet the federal standard for child-resistant packaging. Specifically, the packaging fails to comply with the requirements of the Poison Prevention Packaging Act (PPPA). This act was established precisely to prevent accidental ingestions by young children, and it mandates that certain hazardous substances, including many prescription drugs, be packaged in containers that are difficult for children under five years old to open, yet still accessible to adults.
The core issue here is not with the medication itself—Sandimmune® and Neoral® are effective treatments when taken as directed—but with the outer shell designed to hold them. Blister packs are a common delivery method for pills and soft gelatin capsules because they protect the drug from moisture and air. However, not all blister packs are created equal. Standard blister packs often rely on simple pressure or tearing to open, which can sometimes be manipulated by curious toddlers who have developed the dexterity to peel back the foil or push through the plastic. Child-resistant packaging, by contrast, requires a specific combination of actions—such as pushing down while turning—that is mechanically complex enough to frustrate a young child’s developing motor skills. Because these particular 100 mg packages lack that necessary complexity, they can be opened with relative ease by a child.
When the packaging fails in this way, the mechanism of harm is straightforward and severe. Cyclosporine, the active ingredient in both Sandimmune® and Neoral®, is an immunosuppressant. While it is a vital drug for transplant patients to prevent organ rejection, it is also potent. If a young child manages to open these non-compliant blister packages and swallows even a small number of the soft gelatin capsules, the result can be acute poisoning. Children have much lower body weights than adults, meaning a dose that might be therapeutic for a patient could be toxic or even fatal for a toddler.
The risk is particularly insidious because the symptoms of poisoning from cyclosporine may not be immediately obvious to a parent who doesn’t suspect an ingestion occurred. The child might appear fine at first, but internal damage can begin quickly. This is why the CPSC emphasizes that the failure to meet the child-resistant requirement is a critical safety gap. It removes the primary physical barrier designed to keep dangerous substances out of reach of the most vulnerable members of the household. While no incidents have been reported yet with these specific lots, the potential for harm exists the moment a package is within reach and can be opened by a small hand.
Who is most at risk
While this recall was initiated by Novartis to address a specific packaging compliance issue rather than a defect in the medication itself, the potential consequences of the error are severe for a very specific demographic: young children. The primary group at immediate risk of poisoning from these recalled Sandimmune and Neoral blister packages are toddlers and preschoolers, typically between the ages of one and four years old. This age group is naturally curious, explores their environment by putting objects in their mouths, and lacks the cognitive ability to understand that prescription medications are dangerous if ingested incorrectly. Because the recalled packaging fails to meet the stringent child-resistant standards required by the Poison Prevention Packaging Act (PPPA), it does not provide the necessary barrier that would otherwise prevent a determined child from accessing the soft gelatin capsules inside.
The vulnerability of this group is amplified by the physical nature of the product. Sandimmune and Neoral are cyclosporine medications, which are powerful immunosuppressants used to prevent organ rejection in transplant patients or to treat certain autoimmune conditions. Even a small amount of cyclosporine can be toxic to a small child. Soft gelatin capsules, like those contained in the recalled 100 mg blister packs, may look appealing to a child due to their smooth texture and sometimes familiar appearance, similar to candy or vitamins. Without the complex opening mechanism required by child-resistant standards, these packages could be opened with relative ease by a young hand, leading to accidental ingestion. The risk is not just about access; it is about the rapid onset of poisoning symptoms, which can include nausea, vomiting, and more serious systemic effects that require immediate medical intervention.
While children are the primary concern for accidental poisoning, other household members may also be indirectly affected by this packaging failure. In homes where both elderly individuals or those with limited dexterity take these medications, non-child-resistant packaging can sometimes present its own set of challenges. Although the recall is driven by the lack of child-proofing, it is worth noting that standard child-resistant closures are designed to require a specific combination of strength and coordination (push-and-turn) that young children cannot replicate but adults generally can manage. The absence of these features means that while the pack may open too easily for a child, it does not necessarily mean it is difficult for an adult with arthritis or reduced grip strength, though the primary safety failure here remains the lack of protection against small hands.
Furthermore, families who share living spaces with both transplant patients and young children are in the most precarious position. These households must manage high-stakes medical regimens alongside the unpredictable behavior of toddlers. The recalled blister packages, which contain either three cards of ten capsules or five cards of six capsules depending on whether they are Sandimmune or Neoral, represent a significant quantity of medication accessible within a single container. If a child gains access to just one capsule, the risk is real and immediate. Therefore, the "who" in this scenario is not just any child, but specifically those living in homes where these specific 100 mg prescription drugs are stored and where there is no other secure, out-of-reach storage solution already in place.
It is also important to recognize that the risk extends beyond the home environment to any setting where these medications might be left unattended, such as in a car, a guest room, or a shared living area. The lack of child-resistant packaging means that standard safety habits, like closing a pill bottle tightly, may not have been sufficient to deter a young explorer. This is why the remedy provided by Novartis—providing free child-resistant pouches—is critical. It restores the protective layer that was missing from the original package, ensuring that even if a child finds the medication, they cannot easily open it. For caregivers and parents, understanding this specific risk profile helps in prioritizing the immediate securing of these medications while waiting for the corrective pouches to arrive.
How to tell if you have the recalled item
Identifying whether your medication is part of this specific recall requires a careful, step-by-step check of your prescription bottles and blister packs. Because the issue involves only 100 mg doses of two specific brands manufactured by Novartis, it is crucial not to rely on general assumptions about your medication. Even if you take Sandimmune or Neoral for an ongoing condition, you may have non-recalled batches with different packaging, dosages, or expiration dates. The most reliable way to confirm your status is to examine the physical labels on the outer box and the individual blister cards inside.
First, verify that you are holding one of the two affected products: Sandimmune® (cyclosporine capsules, USP) 100 mg soft gelatin capsules or Neoral® (cyclosporine capsules, USP) MODIFIED 100 mg soft gelatin capsules. The dosage strength is critical; this recall does not apply to other strengths of these drugs. Next, look for the National Drug Code (NDC) number printed on the outer package and on the blister cards themselves. For Sandimmune®, the recalled NDC numbers are 0078-0241-15 and 0078-0241-61. For Neoral®, the relevant NDC numbers are 0078-0248-15 and 0078-0248-61. If your NDC number does not match these specific codes, your product is likely not part of this recall.
Even if the NDC matches, you must cross-reference the lot number and expiration date to be certain. The recall is limited to specific lots with the following identifiers: For Sandimmune®, the affected lot numbers are APCA136 (expiration 09/2020), APCA339 (expiration 02/2021), APCA793 (expiration 01/2022), and APCC238 (expiration 07/2022). For Neoral®, the affected lot numbers are APCA437 (expiration 07/2020) and APCA979 (expiration 03/2021). The packaging will clearly display "Novartis," the medication name, dosage, NDC, lot number, and expiration date on both the outer carton and the blister cards. If your lot number or expiration date falls outside these ranges, or if your NDC differs, you are safe from this specific packaging defect.
If you find that your medication matches these criteria, do not panic, but do act promptly. The hazard is that the current blister packages fail to meet child-resistant packaging requirements mandated by the Poison Prevention Packaging Act. While this does not mean the medication itself is defective or ineffective, it does mean it poses a poisoning risk if accessible to young children. Once confirmed, immediately secure the product out of sight and reach of children while you arrange for the free child-resistant pouches offered by Novartis.
What to do — step by step
If you have been prescribed Sandimmune® or Neoral® in the specific 100 mg blister package formats described in this recall, your immediate priority is safety and securing the medication properly. The good news is that you do not need to discard these medications or stop taking them abruptly. These drugs are critical for managing your condition, and stopping them without medical guidance can be dangerous. Instead, follow these concrete steps to protect your household while maintaining your treatment plan.
Step 1: Secure the medication immediately. The core issue with this recall is that the blister packages do not meet the federal child-resistant packaging standards required by law. This means a determined toddler or young child could potentially open them and ingest the capsules, leading to serious poisoning. As soon as you realize you have one of the affected packages, move it to a location that is completely out of sight and out of reach of children. Do not leave it in an easily accessible cabinet, on a nightstand, or in a bathroom medicine closet that kids can open. Think of it like locking away chemicals or sharp objects; treat this specific packaging with the same level of caution until you have applied the remedy. If you have other family members who care for children, let them know immediately so they are aware of the risk.
Step 2: Contact Novartis to request a free child-resistant pouch. You do not need to return the blister packages themselves to get help; instead, you need to obtain the protective storage solution. Novartis is providing free child-resistant pouches specifically designed to hold these non-compliant blister cards safely. You can reach their dedicated recall team by calling their toll-free number at 866-629-6182. Their representatives are available daily from 8 a.m. to 8 p.m. Eastern Time, making it easy to find a time that works for you. Alternatively, if you prefer written communication or need to send documentation, you can email them directly at Novartis5060@stericycle.com. When you contact them, clearly state that you are participating in the recall for 100 mg Sandimmune and Neoral blister packages so they can process your request efficiently.
Step 3: Transfer the medication to the pouch and continue use as directed. Once you receive the child-resistant pouch, carefully place the entire blister card inside it. Ensure the pouch is sealed tightly according to the instructions provided with the pouch. This creates a dual-layer of safety: the original packaging holds the drug, and the pouch prevents accidental access by children. You may continue to take your medication exactly as prescribed by your doctor during this transition period. The recall is about packaging safety, not drug efficacy or contamination. Keep using the medication until you have spoken with your healthcare provider about any future refill needs, at which point they should be able to dispense new batches that come in compliant child-resistant blister packaging.
Step 4: Monitor for updates and dispose of old packaging properly. Stay informed by checking the Novartis news statements page linked on their official website or visiting the specific corrective action URL provided in the recall notice. This ensures you know when new, compliant packaging will be available for your next refill. When the time comes to replace this medication, follow your pharmacist’s instructions on how to dispose of the old, recalled blister packages safely. Do not throw them in regular household trash where they might be accessed by children or pets before disposal is complete. By following these steps, you protect your loved ones from potential poisoning risks while ensuring your own health remains uninterrupted.
Your refund, repair, or replacement options
When you encounter a product recall, the immediate question on most people’s minds is often, “What do I do with this item, and will I get my money back?” In the case of this specific recall involving Novartis’ 100 mg Sandimmune and Neoral prescription drugs, the remedy is designed to prioritize your safety without penalizing you for a packaging defect. It is important to understand that this is not a situation where the medication itself is defective or harmful; rather, the outer blister packaging failed to meet federal child-resistant standards. Because of this distinction, Novartis has arranged a specific solution that allows you to keep using the life-saving medication while addressing the safety gap.
First and foremost, there is no requirement for you to return the physical blister packages to the company for a refund or credit. The recall notice explicitly states that consumers can continue to use the medication exactly as directed by their healthcare provider. The primary remedy provided is a free child-resistant pouch. This pouch serves as a temporary "repair" to the packaging system, effectively restoring the safety barrier that was missing from the original blister pack. You are encouraged to secure the product out of the sight and reach of children immediately, but you do not need to discard the medication or seek a replacement bottle from your pharmacy right away.
To obtain these free child-resistant pouches, you must contact Novartis directly. The company has set up dedicated channels for this purpose to ensure that affected customers can easily secure the necessary safety materials. You have three convenient ways to reach them:
- Toll-Free Phone: Call 866-629-6182. They are available daily from 8 a.m. to 8 p.m. Eastern Time.
- Email: Send a request to Novartis5060@stericycle.com.
- Online: Visit www.pharma.us.novartis.com, navigate to the News tab, click on Statements, or go directly to https://www.pharma.us.novartis.com/news/statements/corrective-action-certain-100-mg-sandimmune-and-neoral-blister-packages-us.
When you contact Novartis, they will coordinate the distribution of the child-resistant pouches. These pouches are intended to be used to store these specific blister package medications until new, compliant child-resistant blister packaging becomes available to your pharmacy or provider. This interim solution ensures that your treatment is not interrupted while the packaging issue is resolved. Please note that the recall facts do not mention any automatic mail-back labels or prepaid shipping instructions for returning the original packages; therefore, you should follow the specific instructions provided by the Novartis representative when you call or email them. If you have questions about how to properly use the pouch or what to expect next, the customer service team is your best resource.
While this recall does not involve a monetary refund because the drug itself is safe and effective, the provision of free safety equipment is a significant value add for consumers. It underscores that the company is taking responsibility for the packaging failure without burdening you with additional costs or logistical hurdles. By securing these pouches promptly, you ensure that your household remains protected from potential poisoning risks while you continue your prescribed therapy uninterrupted.
What can happen if you ignore it
When a recall involves prescription medication packaging, the stakes are significantly higher than with many other consumer product failures. In this specific case involving Novartis’s Sandimmune and Neoral blister packages, the core issue is that the outer container does not meet the rigorous standards set by the Poison Prevention Packaging Act (PPPA). While these standard containers are designed to be difficult for young children to open, they are not impossible for them to figure out. If you choose to ignore this recall and continue using the non-compliant packaging without taking additional precautions, you are leaving a critical layer of defense against accidental ingestion wide open.
The primary consequence of ignoring this warning is the elevated risk of pediatric poisoning. Cyclosporine, the active ingredient in both Sandimmune and Neoral, is an immunosuppressant medication that works by suppressing the body’s immune system. While this is therapeutic for transplant patients or those with autoimmune conditions, it is highly toxic if ingested by someone who does not need it. For a young child, even a small amount of cyclosporine can cause severe health complications. Because children are naturally curious and may not understand the danger of pills that look like candy or small snacks, the inability to easily open the recalled blister pack increases the likelihood that they will successfully access the medication.
If a child were to swallow these capsules, the medical consequences could be serious and potentially life-threatening. Symptoms of cyclosporine poisoning can include nausea, vomiting, diarrhea, and in more severe cases, kidney damage or neurological effects. The urgency here is not just about inconvenience; it is about preventing acute medical emergencies that would require immediate hospitalization. Although the CPSC report notes that no incidents have been reported to date, this absence of data does not guarantee safety. It simply means that, so far, caregivers have managed to keep these specific packages out of reach or children have not yet accessed them. Relying on luck is a dangerous strategy when dealing with potent pharmaceuticals.
Furthermore, ignoring the remedy leaves you without the free child-resistant pouches that Novartis is providing. These pouches are specifically engineered to meet safety standards that the original blister packaging failed to achieve. By continuing to use the recalled items as-is, you are effectively bypassing a free, government-mandated safety upgrade. The risk compounds over time; the longer you wait to transfer the medication to a compliant container, the more opportunities there are for an accident to occur in a busy household where toddlers are exploring their environment.
Finally, consider the psychological burden of living with this uncertainty. Knowing that your child’s life-saving or essential medication is stored in a package that experts have deemed unsafe can create unnecessary anxiety. The recall process is designed to eliminate that worry entirely by providing a simple, immediate solution. Choosing not to act means carrying the responsibility of preventing access without the proper tools, which is an unfair and risky burden for any caregiver to bear. The path of least resistance here—the quickest way to secure your family’s safety—is to follow the recall instructions immediately rather than risking a preventable tragedy.